DJI-136

N/A

Report date: 2026/05/23 20:00:57

Base Information

Drug NameDJI-136

Drug Alias NameDJI136DJI-136

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionDelta-like protein 3 modulatorsT lymphocyte replacements

TargetsDelta-like protein 3

Therapy Area/IndicationsSmall Cell Lung Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingapore

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesNovartis Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag

Inactive CompaniesN/A

Active IndicationsSmall Cell Lung Carcinoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A